R. Jonathan Henderson, MD

R. Jonathan Henderson, MD

Regional Urology, LLC

Shreveport, Louisiana

Dr. Henderson is a urologist with Regional Urology, LLC, in Shreveport, Louisiana. He obtained a Bachelor of Science Degree in Microbiology from Louisiana State University in Baton Rouge. After receiving his MD from LSU Medical Center in Shreveport, he then completed his Internship and Residency in Urology at LSUMC Hospital. During this time, he also authored a number of papers and presentations. Dr. Henderson spent the next six years in practice in Alabama, where he specialized in laparoscopy and treating disorders of the female bladder. During this time, he served as a representative of Alabama in the Southeastern Section of the American Urology Association. He also served as an Assistant Clinical Professor of Urology at the University of Alabama in Tuscaloosa. Dr. Henderson is certified by the American Board of Urology. He is a member of the American Urologic Association, the Shreveport Medical Society, the Louisiana State Medical Society, the Society of Laparoscopic Surgeons, and the Alpha Omega Alpha Medical Honor Society. He has been on the LUGPA Board of Directors since 2011, and is currently serving as Secretary.


Talks by R. Jonathan Henderson, MD

LUGPA Government Policy Panel: Overview

R. Jonathan Henderson, MD, a urologist with Regional Urology, LLC, in Shreveport, Louisiana, discusses the Large Urology Group Practice Association, or LUGPA, the only nonprofit urology trade association in the United States. Dr. Henderson, who is the current President of LUGPA, explains LUGPA’s mission to preserve and advance the independent practice of urology; its core values of quality, collaboration, innovation, and integrity; and its strategic priorities, including advocacy and health policy, value-based care, practice management and benchmarking, and leadership development. Dr. Henderson expounds upon LUGPA’s dyad leadership model, wherein a practice is run by both a physician leader and an administrator, and he asserts this results in stronger practices, both medically and businesswise. Dr. Henderson then promotes Practice Management for Urology Groups, LUGPA’s Guidebook as a “recipe book for what we do in urology” before summarizing LUGPA’s benchmarking and executive leadership programs. Turning to the future, Dr. Henderson says LUGPA is following innovation and breakthroughs in urologic care, cost containment pressures, evolving payment methods, and practice and hospital integration and consolidation. He highlights health care personnel (HCP) shortages, citing data to support his assertion that it is a “perfect storm,” with 277 urologists completing residency annually, 2,000-3,000 current US job openings, and an average urologist age of 58. Dr. Henderson concludes by discussing the LUGPA 2021 Annual Meeting as well as new virtual offerings spurred by the COVID-19 pandemic, emphasizing LUGPA’s value in facilitating powerful networks and its relevance to all urology practitioners, whether they be academic, hospital-based, independent, or employed.

Read More

Genetics and Genomic Biomarkers: How Molecular Markers and mpMRI Play a Role

R. Jonathan Henderson, MD, a urologist with Regional Urology, LLC, and President-Elect of the LUGPA Board of Directors, discusses the challenges posed by having a plethora of screening tools at a physician’s disposal, as well as how the statistical validity of these tools makes it unclear as to which are best for a given situation. He also uses his personal experience with taking a patient through the prostate cancer screening process in order to highlight the need for free and open communication with the patient, the importance of choosing a process that the physician is comfortable with, and the challenge of helping the patient find peace of mind.

Read More

Challenging Cases in Advanced Prostate Cancer: nmCRPC

R. Jonathan Henderson, MD, a urologist with Regional Urology, LLC, discusses an unusual case of non-metastatic castration-resistant prostate cancer (nmCRPC) with a panel featuring Laurence Klotz, MD, FRCSC, Daisaku Hirano, MD, and Michael S. Cookson, MD. The case in question involves an asymptomatic patient in his 70s who was successfully treated for localized prostate cancer and then, ten years later, was treated with cryotherapy for recurrent cancer, after which point cancer stopped appearing in imaging, but the patient’s PSA rapidly rose even as he was treated with abiraterone. Drs. Klotz, Hirano, and Cookson discuss whether it is appropriate to give such treatments to a persistently asymptomatic patient and note that his high PSA could be a response to abiraterone. They also consider the possibility that advanced imaging techniques like PSMA-PET would reveal that the man does have metastases and ponder which of the approved treatments for nmCRPC might suit this patient best.

Read More

The LUGPA Alternative Payment Model (APM) on Newly Diagnosed PCa and the Role of Active Surveillance

R. Jonathan Henderson, MD, summarizes the Large Urology Group Practice Association’s (LUGPA’s) efforts to develop an alternative payment model (APM) for urologists treating newly diagnosed prostate cancer patients. He explains the roadblocks to reaching this goal, including conflicts with the Physician-Focused Payment Model Technical Advisory Committee (PTAC).

Read More

Join the GRU Community

- Why Join? -